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abstract
PURPOSE To evaluate the impact of surgeon-assessed extent of primary tumor resection on local progression and
survival in patients in the International Society of Pediatric Oncology Europe Neuroblastoma Group High-Risk
Neuroblastoma 1 trial.
PATIENTS AND METHODS Patients recruited between 2002 and 2015 with stage 4 disease. 1 year or stage 4/4S
withMYCN amplification, 1 year who had completed induction without progression, achieved response criteria
for high-dose therapy (HDT), and had no resection before induction were included. Data were collected on the
extent of primary tumor excision, severe operative complications, and outcome.
RESULTS A total of 1,531 patients were included (median observation time, 6.1 years). Surgeon-assessed extent
of resection included complete macroscopic excision (CME) in 1,172 patients (77%) and incomplete mac-
roscopic resection (IME) in 359 (23%). Surgical mortality was 7 (0.46%) of 1,531. Severe operative compli-
cations occurred in 142 patients (9.7%), and nephrectomy was performed in 124 (8.8%). Five-year event-free
survival (EFS) 6 SE (0.40 6 0.01) and overall survival (OS; 0.45 6 0.02) were significantly higher with CME
compared with IME (5-year EFS, 0.336 0.03; 5-year OS, 0.376 0.03; P, .001 and P5 .004). The cumulative
incidence of local progression (CILP) was significantly lower after CME (0.17 6 0.01) compared with IME
(0.306 0.02; P, .001). With immunotherapy, outcomes were still superior with CME versus IME (5-year EFS,
0.476 0.02 v 0.396 0.04; P5 .038); CILP was 0.146 0.01 after CME and 0.276 0.03 after IME (P, .002).
A hazard ratio of 1.3 for EFS associated with IME compared with CME was observed before and after the
introduction of immunotherapy (P 5 .030 and P 5 .038).
CONCLUSION In patients with stage 4 high-risk neuroblastoma who have responded to induction therapy, CME of
the primary tumor is associated with improved survival and local control after HDT, local radiotherapy (21 Gy),
and immunotherapy.
J Clin Oncol 38:2902-2915. © 2020 by American Society of Clinical Oncology
INTRODUCTION
Despite recent therapeutic advances, many patients
with high-risk neuroblastoma will not be long-term
survivors1-6; their outcome needs to be improved.
The current therapeutic multimodality approach
comprises induction chemotherapy; therapy to the site
of the primary tumor (surgical excision and radio-
therapy); high-dose therapy (HDT) with hematopoietic
stem-cell rescue (SCR); and residual disease therapy,
including immunotherapy.1-6 To date, clinical trials have
focused on induction, HDT, and immunotherapy,1-7
with less attention directed to local therapy, and
there have been no randomized trials to examine the
effect of the extent of excision of the primary tumor.
Although challenging and time consuming, complete
macroscopic excision (CME) can be performed for the
most extensive tumors with low morbidity and mor-
tality.8 However, there are conflicting reports9-19 as to
the benefit.
The primary aim of this analysis was to determine the
relationship between the extent of surgeon-assessed
primary tumor resection and event-free survival (EFS),
overall survival (OS), and local progression (cumulative
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stage 4 high-risk neuroblastoma who were treated in the
International Society of Pediatric Oncology Europe Neu-
roblastoma Group High-Risk Neuroblastoma 1 (HR-NBL1/
SIOPEN) trial.
PATIENTS AND METHODS
Patients included in this study were enrolled on the HR-
NBL1/SIOPEN trial from June 2002 to December 2015
who fulfilled the eligibility criteria: stage 4 . 1 year or
stage 4 or 4S withMYCN amplification, 1 year; completion
of rapid COJEC (cisplatin, vincristine, carboplatin, etoposide,
and cyclophosphamide)1,7,20 induction without progression;
and no resection before induction, surgery, and achieve-
ment of the criteria for HDT1 (complete bone marrow re-
mission and at least a partial metastatic response at skeletal
sites on 123I-metaiodobenzylguanidine [MIBG] scintigra-
phy). If these criteria were not achieved, two courses of
topotecan, vincristine, and doxorubicin (TVD)21 were given
(Fig 1). No patients were given specific therapy for tumors
with anaplastic lymphoma kinase aberrations.
In patients fulfilling the criteria for HDT, CME of the primary
tumor was recommended. Postponement of operation until
after HDT/SCR was permitted if the tumor was deemed
unresectable. From June 2002 to October 2010, eligible
patients were randomly assigned to receive busulfan and
melphalan (BuMel) or carboplatin, etoposide, and mel-
phalan as HDT.1 After October 2010, in view of the results
of randomization, all patients received BuMel.1,2
After HDT/SCR, radiotherapy (21 Gy in 14 fractions over 18-
20 days) was given to the preoperative volume of the pri-
mary tumor and involved regional lymph nodes regardless
of the degree of surgical resection. No dose modification
was used in the event of incomplete tumor excision, and
metastatic sites were not irradiated. Omission of radio-
therapy was discussed with the radiotherapy coordinators if
the primary tumor was considered unsuitable because of
the site and the volume.
From June 2002 to September 2009, all patients were
given isotretinoin orally after completion of radiotherapy.
From October 2009 to August 2013, patients were ran-
domly assigned to dinutuximab beta and isotretinoin or
dinutuximab beta with subcutaneous interleukin 2 and
isotretinoin.2 From September 2013 to December 2015,
patients received dinutuximab beta and isotretinoin.
The primary end points and description of the protocol have
been published.1,2,20 Biologic features were determined in
SIOPEN reference laboratories.22,23 Response to treatment
was largely determined by computed tomography (CT)
postcontrast enhanced scanning and assessed using In-
ternational Neuroblastoma Response Criteria.24
Parents/guardians and patients according to age provided
written informed consent for treatment, data collection, and
analysis. The trial was approved by national regulatory
authorities and by national and institutional ethical com-
mittees and/or review boards.
Surgery
The protocol strongly encouraged CME of the primary tu-
mor ideally before HDT. Removal of all visible and palpable
tumor, including related involved lymph nodes, was defined
as CME. When visible or palpable tumor remained after
attempted excision, the procedure was defined as in-
complete macroscopic excision (IME), irrespective of the
volume of remaining tumor. If nephrectomy was deemed
necessary to obtain CME, the operation could be postponed
until after HDT to preserve renal function. Tumor resection
was permitted at 1 of 3 time points:, 60 days after the end




This study investigated the influence of surgical excision on the outcome of a large (1,531) cohort of patients, enrolled by
128 institutions in 18 countries, with high-risk neuroblastoma treated in the International Society of Pediatric Oncology
Europe Neuroblastoma Group High Risk-Neuroblastoma 1 trial.
Knowledge Generated
In both the pre- and the postimmunotherapy eras, there was a higher overall and event-free survival and a lower cumulative
incidence of local progression in patients with complete, compared with incomplete, macroscopic excision of the primary
tumor. Furthermore, complete macroscopic excision was accompanied by low severe operative complication (9.7%) and
mortality (0.46%) rates.
Relevance
In patients with high-risk neuroblastoma in the context of an intensive chemotherapy regimen followed by high-dose
therapy, local radiotherapy (21 Gy), and immunotherapy, the goal of surgery should be complete surgical excision of
the tumor.
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Retinoic acid Isotretinoin 160 mg/m2/d divided into 2 equal doses given orally twice a day for 14 days





1.5 mg/m2 (maximum dose 2 mg) × 1 day 
750 mg/m2 × 1 day
175 mg/m2 × 2 days
A
Course B Vincristine 
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1.5 mg/m2 (maximum dose 2 mg) × 1 day 






1.5 mg/m2 (maximum dose 2 mg) × 1 day 
175 mg/m2 × 2 days








1.5 mg/m2 × 5 days
2 mg/m2/ctn over 48 hours




< 9 kg: 1 mg/kg; 9 to < 16 kg: 1.2 mg/kg; 16-23 kg: 1.1 mg/kg; > 23 to 34 kg: 0.95 mg/kg; > 34 kg: 0.8 mg/kg × 5 days
> 34 kg: 0.8 mg/kg × 5 days
140 mg/m2 × 1 day
BuMel/SCR
Radiotherapy Fractionated radiotherapy (21 Gy) given in 14 fractions of 1.5 Gy over not more than 21 daysRT






AUC  4.1 mg/mL per min per day for 4 days (based on the GFR rate)
12 kg: 11.3 mg/kg/d; > 12 kg: 338 mg/m2/d × 4 days
12 kg: 2.3 mg/kg/d; > 12 kg: 70 mg/m2/d × 3 days
CEM/SCR
Immunotherapy ch14.18/CHO 20 mg/m





FIG 1. HR-NBL1/SIOPEN treatment overview. AUC, area under the concentration curve; ch14.18/CHO, dinutuximab beta; COJEC, cisplatin,
vincristine, carboplatin, etoposide, and cyclophosphamide; ctn, continuous infusion; GFR, glomerular filtration rate; IL-2, interleukin 2; SCR,
stem-cell rescue; TP, time point. (*) Infants and children with a body weight, 12 kg will be dosed at 0.67mg/kg/d. In infants weighing# 5 kg, an
additional one-third dose reduction is advised.
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Operations were performed in designated pediatric on-
cology centers by surgeons who were cognizant of the
challenges and goals of the study. The feasibility of tumor
excision was judged by multidisciplinary teams (pediatric
surgeons, oncologists, radiologists, and radiation oncolo-
gists) at each treating institution. Because patients with
high-risk neuroblastoma frequently exhibit preoperative
image-defined risk factors (IDRFs25-28; previously termed
surgical risk factors25), even after induction, their presence
was not considered a contraindication to operation.
The operation principles, as described by Kiely,29 were to
display natural anatomy by reflecting overlying viscera then
dissecting along the plane of major blood vessels from
areas free from tumor encasement toward the disease.
Operation-Related Data and Definitions
Data were collected on presence of IDRFs, completeness of
tumor excision (determined by the surgical team at the
conclusion of the operation), severe operative complica-
tions, nephrectomy, death within 30 days as a result of the
operation or any cause, local progression or relapse, and
a second neoplasm. Two-dimensional imaging (largely CT
scanning) was used to identify IDRFs,25-28 which were
deemed present if the tumor surrounded a vital structure,
typically a major blood vessel.27 Because the SIOPEN ra-
diology committee did not consider the sensitivity of con-
temporary imaging reliable enough to distinguish the effects of
operation, including edema and hematoma, from residual
tumor, postoperative imaging was not routinely used. Hem-
orrhage. 30%of blood volume, vascular injury leading to loss
of tissue, major ascites or pleural effusion, spinal cord injury,
peripheral nerve injury leading to loss of function, and any
organ failure were recorded as severe operative complications.
Statistical Analysis
Median follow-up time was calculated using the reverse
Kaplan-Meier estimate.30 The Kaplan-Meier method was
used to estimate EFS and OS. EFS was defined as the time
from diagnosis to the first occurrence of relapse, pro-
gression, secondary malignancy, or death; OS was defined
as death as a result of any cause. Patients with no event
were censored at the date of their last follow-up. For sta-
tistical comparisons, log-rank test and Cox regression31
were used for the entire cohort and separately for pa-
tients included from June 2002 to June 2009 and patients
included from July 2009 to December 2015. CILP was
estimated in consideration of local relapse, local progres-
sion, or death as a result of progression of the primary tumor
as event and while taking into account the competing risk of
isolated distant relapse, disease progression, and death as
a result of causes other than relapse.31 The statistical com-
parison of cumulative incidences was done using Gray’s test
and the Fine and Graymodel.32 Unless otherwise stated, data
are given as mean6 SE. EFS, OS, and CILP are presented as
3-year and 5-year point estimates with standard errors.
The number of metastatic compartments (MCs) at di-
agnosis either in bone marrow, in skeleton, or in another
site with a range from 1 to 6 was calculated for each patient.
The size of the treatment center was grouped up to 10 or
. 10 according to the total number of patients treated at
that center over the study period. The relationship between
surgical excision and patient and treatment characteristics
was evaluated using x2 test. Kendall’s t was used to explore
the correlation between surgical excision and IDRFs and
serious complications. Statistical analysis was performed
with SAS 9.4 software (SAS Institute, Cary, NC), and the
analysis was performed in August 2019.
RESULTS
The characteristics of the 1,531 patients who fulfilled the
criteria (Data Supplement) are listed in Table 1. The me-
dian follow-up time after operation was 6.1 years. Patients
were enrolled from 128 SIOPEN institutions (Data Sup-
plement) in 18 countries using the SIOPEN-R-NET web-
based system.33
Time Point of Operation
Surgical resection was attempted at the EOI in 923 patients
(60%), after TVD in 393 (26%), and after HDT in 215 (14%;
Table 1; Fig 1).
Outcome of Operation
CME was achieved in 1,172 patients (77%) and IME in 359
(23%). There was CME in 85% in the absence of IDRFs
compared with 74% in their presence (P, .001). CME was
higher in patients with adrenal compared with nonadrenal
abdominal tumors (P , .001) and with MYCN-amplified
tumors (Table 1). Treatment period, timing of operation,
and treatment center size were not significantly related to
the CME (Table 1).
Surgical Complications
There were 7 operation-related deaths (0.46%): intestinal
ischemia (n 5 2), major vascular injury (n 5 2), liver is-
chemia (n 5 1), bilateral renal ischemia (n 5 1), and
multisystem organ failure (n 5 1). There was no difference
in the number of operative deaths between CME (3 [0.26%]
of 1,172 patients) and IME (4 [1.1%] of 359 patients; P 5
.056 by Fisher’s exact test). Data on operative severe
complications were available for 1,464 patients (96%).
Severe surgical complications (not including nephrectomy)
occurred in 142 (9.7%) of 1,464 patients, 89 (7.9%) of 1,128
with CME, and 53 (15.8%) of 336 with IME (P , .001).
Nephrectomy was performed in 124 (8.8%) and was signifi-
cantly less with CME (86 [7.9%] of 1,083) v 38 (11.9%) of 319
with IME (P 5 .028). Twenty of 142 patients with severe
complications also had anephrectomy. The relationship among
extent of surgical resection, IDRFs, and severe complications is
shown in the Data Supplement.
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TABLE 1. Patient Characteristics and Treatment
Characteristic and Treatment Total, No. CME, No. (%) IME, No. (%) P a
No. of patients 1,531 1,172 (77) 359 (23)
Sex
Female 626 463 (74) 163 (26) .0470
Male 905 709 (78) 196 (22)
Age, years
, 1 77 63 (82) 14 (18) .0050
1-1.5 148 123 (83) 25 (17)
1.5-5 1,018 780 (77) 238 (23)
. 5 288 206 (72) 82 (28)
# 1.5 225 186 (83) 39 (17) .0190
. 1.5 1,306 986 (75) 320 (25)
INSS stage
4 1,521 1,162 (76) 359 (24) .0790
4S MNA 10 10 (100) 0 (0)
MYCN
MNA yes 622 502 (81) 120 (19) .0030
MNA no 810 600 (74) 210 (26)
Missingb 99 70 (71) 29 (29)
Primary tumor site
Cervical
Yes 50 36 (72) 14 (28) .4400
No 1,481 1,136 (77) 345 (23)
Thoracic
Yes 181 128 (71) 53 (29) .0490
No 1,350 1,044 (77) 306 (23)
Adrenal
Yes 1,109 894 (81) 215 (19) , .0001
No 422 278 (66) 144 (34)
Nonadrenal abdominal
Yes 491 341 (69) 150 (31) , .0001
No 1,040 831 (80) 209 (20)
Pelvic
Yes 82 55 (67) 27 (33) .0370
No 1,449 1,117 (77) 332 (23)
IDRFs
Yes 1,097 814 (74) 283 (26) , .0001
No 337 287 (85) 50 (15)
Missingb 97 71 (73) 26 (27)
No. of MCs
1 182 137 (75) 45 (25) .6490
. 1 1,203 924 (77) 279 (23)
Missingb 146 111 (76) 35 (24)
(continued on following page)
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TABLE 1. Patient Characteristics and Treatment (continued)
Characteristic and Treatment Total, No. CME, No. (%) IME, No. (%) P a
TVD
Not given 1,040 814 (78) 226 (22) .0210
Given 491 358 (73) 133 (27)
Surgery
EOI , 60 days after cycle 8 923 723 (78) 200 (22) .1280
After TVD or . 60 days after cycle 8 393 290 (74) 103 (26)
After HDT 215 159 (74) 56 (26)
Severe operative complications
Yes 142 89 (63) 53 (37) , .0010
No 1,322 1,039 (79) 283 (21)
Missingb 67 44 (66) 23 (34)
Nephrectomy
Yes 124 86 (69) 38 (31) .0280
No 1,278 997 (78) 281 (22)
Missingb 129 89 (69) 40 (31)
HDT
BuMel 1,053 816 (77) 237 (23) .3590
CEM 255 200 (78) 55 (22)
Other 2 2 (100) 0 (0)
No HDT 80 56 (70) 24 (30)
Type of HDT missingb 141 98 (70) 43 (30)
Radiotherapy
Done 1,153 893 (77) 260 (23)
Not done 156 116 (74) 40 (26) .4560
Missingb 222 163 (73) 59 (27)
Dinutuximab beta
Given 407 317 (78) 90 (22) .4580
Not given 1,124 855 (76) 269 (24)
Metastatic CR at EOI
Yes 468 365 (78) 103 (22) .3580
No 950 720 (76) 230 (24)
Missingb 113 87 (77) 26 (23)
Treatment period
June 2002-June 2009 743 574 (77) 169 (23) .5280
July 2009-December 2015 788 598 (76) 190 (24)
Center size, patients
# 10 465 369 (79) 96 (21) .0870
. 10 1,066 803 (75) 263 (25)
Abbreviations: BuMel, busulphan and melphalan; CEM, carboplatin, etoposide, and melphalan; CME, complete macroscopic excision; CR,
complete response; EOI, end of induction; HDT, high-dose therapy; IDRF, image-defined risk factor; IME, incomplete macroscopic excision;
INSS, International Neuroblastoma Staging System; MC, metastatic compartment; MNA,MYCN amplification; TVD, topotecan, vincristine, and
doxorubicin.
aP values by x2 test.
bPatients with missing values are not included in the calculation of the P value.
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CME 1,172 701 0.40 6 0.01 , .001 614 0.45 6 0.01 .004 194 0.17 6 0.01 , .001
IME 359 243 0.33 6 0.03 217 0.37 6 0.03 109 0.30 6 0.02
Age, years
, 1 77 31 0.58 6 0.06 .002 29 0.60 6 0.06 .020 5 0.07 6 0.03 .029
1-1.5 148 78 0.48 6 0.04 71 0.51 6 0.04 23 0.16 6 0.03
1.5-5 1,018 630 0.38 6 0.02 552 0.43 6 0.02 211 0.21 6 0.01
. 5 288 205 0.28 6 0.03 179 0.34 6 0.03 64 0.22 6 0.02
# 1.5 225 109 0.51 6 0.03 .002 100 0.54 6 0.03 .017 28 0.13 6 0.02 .008
.1.5 1,306 835 0.36 6 0.01 731 0.41 6 0.01 275 0.21 6 0.01
MYCN
MNA no 810 514 0.36 6 0.02 .724 449 0.41 6 0.02 .750 163 0.20 6 0.01 .960
MNA yes 622 367 0.41 6 0.02 333 0.45 6 0.02 124 0.20 6 0.02
IDRFs
No 337 196 0.42 6 0.03 .140 170 0.48 6 0.03 .116 57 0.17 6 0.02 .145
Yes 1,097 684 0.38 6 0.02 604 0.42 6 0.02 224 0.20 6 0.01
MCs
1 182 86 0.54 6 0.04 , .001 77 0.57 6 0.04 , .001 42 0.22 6 0.03 .342
. 1 1,203 782 0.35 6 0.01 695 0.40 6 0.01 238 0.20 6 0.01
Cervical
No 1,481 910 0.38 6 0.01 .530 801 0.43 6 0.01 .604 292 0.20 6 0.01 .697
Yes 50 34 0.30 6 0.07 30 0.34 6 0.08 11 0.24 6 0.06
Thoracic
No 1,350 824 0.39 6 0.01 .223 729 0.43 6 0.01 .516 255 0.19 6 0.01 .015
Yes 181 120 0.32 6 0.04 102 0.40 6 0.04 48 0.27 6 0.03
Adrenal
No 422 280 0.34 6 0.02 .028 244 0.39 6 0.03 .071 109 0.26 6 0.02 .015
Yes 1,109 664 0.40 6 0.02 587 0.45 6 0.02 194 0.18 6 0.01
Nonadrenal abdominal
No 1,040 635 0.39 6 0.02 .342 567 0.43 6 0.02 .813 195 0.19 6 0.01 .134
Yes 491 309 0.37 6 0.02 264 0.43 6 0.02 108 0.22 6 0.02
Pelvic
No 1,449 894 0.38 6 0.01 .857 791 0.43 6 0.01 .447 287 0.20 6 0.01 .870
Yes 82 50 0.42 6 0.06 40 0.50 6 0.06 16 0.18 6 0.04
EOI metastatic response
CR 468 270 0.42 6 0.02 .011 246 0.46 6 0.02 .102 93 0.20 6 0.02 .687
Less than CR 950 606 0.36 6 0.02 525 0.42 6 0.02 194 0.21 6 0.01
Surgery
EOI , 60 days after
cycle 8
923 560 0.40 6 0.02 .149 501 0.44 6 0.02 .659 180 0.19 6 0.01 .227
(continued on following page)
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Influence of Surgical Excision
Five-year EFS (0.40 6 0.01) and 5-year OS (0.45 6 0.02)
were significantly higher with CME compared with IME
(5-year EFS, 0.33 6 0.03; 5-year OS, 0.37 6 0.03; P ,
.001 and P5 .004; Table 2; Fig 2). Local recurrence (CILP)
was significantly lower after CME (0.17 6 0.01) compared
with IME (0.306 0.02; P# .001). Neither severe operative
complications nor nephrectomy had a significant adverse
effect on EFS or OS (Table 2). The EFS and OS of 16
patients with follow-up who had surgical resection but in-
complete details of surgery were not significantly different
from the 1,531 evaluable patients.
Influence of Immunotherapy
Between June 2002 and June 2009, 5-year EFS was
0.33 6 0.02 after CME compared with 0.27 6 0.03 with
IME (hazard ratio [HR], 1.3; 95% CI, 1.0 to 1.6; P5 .030
adjusted for age, MCs, and EOI metastatic response;
Fig 3). Five-year OS was 0.36 6 0.02 after CME com-
pared with 0.296 0.03 with IME (HR, 1.3; 95% CI, 1.0 to
1.6; P 5 .039 adjusted for age, MCs, and EOI metastatic
response; Fig 3), and 5-year CILP was 0.20 6 0.02 for
patients with CME compared with 0.33 6 0.04 for those
with IME (HR, 2.1; 95% CI, 1.5 to 2.9; P , .001).
After the introduction of immunotherapy (June 2009),
5-year EFS was 0.47 6 0.01 after CME and 0.39 6 0.04
after IME (adjusted HR, 1.3; 95% CI, 1.0 to 1.6; P5 .038),
and 5-year OS was 0.54 6 0.02 after CME and 0.45 6
0.02 after IME (adjusted HR, 1.3; 95% CI, 1.0 to 1.7; P 5
.049). CILP was 0.146 0.02 (CME) compared with 0.276
0.03 (IME; HR, 1.8; 95% CI, 1.2 to 2.7; P 5 .002; Fig 3).
Univariable and Multivariable Analyses
Univariable analysis. The extent of excision, MYCN am-
plification, primary tumor site, age at presentation, number
of MCs at diagnosis, presence of IDRFs, EOI metastatic
response, time point of operation, surgical complications,
nephrectomy, center size, and treatment period were ex-
amined for their influence on EFS (Table 2). CME, age
, 1.5 years, adrenal primary tumor, single MC, EOI met-
astatic response, and treatment between July 2009
and December 2015 were all associated with a supe-
rior EFS.
Multivariable analysis (Cox regression). Independent fac-
tors associated with superior EFS were CME, age , 1.5
years, single MC, treatment between July 2009 and De-
cember 2015, and EOI metastatic response (Table 3).
Independent factors associated with superior OS were

















After TVD or .
60 days after cycle
8
393 255 0.34 6 0.02 215 0.40 6 0.03 72 0.19 6 0.02
After HDT 215 129 0.40 6 0.03 115 0.45 6 0.04 51 0.24 6 0.03
Severe operative
complications
No 1,322 820 0.38 6 0.01 .656 718 0.43 6 0.01 .200 262 0.20 6 0.01 .202
Yes 142 87 0.38 6 0.04 84 0.40 6 0.04 34 0.24 6 0.04
Nephrectomy
No 1,278 791 0.38 6 0.01 .649 695 0.43 6 0.01 .460 251 0.20 6 0.01 .307
Yes 124 78 0.36 6 0.04 71 0.40 6 0.05 29 0.23 6 0.04
Center size
# 10 465 276 0.40 6 0.02 .331 242 0.44 6 0.02 .334 76 0.16 6 0.02 .036
. 10 1,066 668 0.38 6 0.02 589 0.42 6 0.02 227 0.21 6 0.01
Treatment period
2002-June 2009 743 524 0.32 6 0.02 , .001 484 0.35 6 0.02 , .001 172 0.23 6 0.02 .004
July 2009-2015 788 420 0.45 6 0.02 347 0.52 6 0.02 131 0.17 6 0.01
Abbreviations: CILP, cumulative incidence of local progression; CME, complete macroscopic excision; CR, complete response; EFS, event-free survival;
EOI, end of induction; HDT, high-dose therapy; IDRF, image-defined risk factor; IME, incomplete macroscopic excision; MC, metastatic compartment; MNA,
MYCN amplification; OS, overall survival; pEFS, probability of event-free survival; pOS, probability of overall survival; TVD, topotecan, vincristine, and
doxorubicin.
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CME, single MC, and treatment period and for CILP, CME
and treatment period.
DISCUSSION
This report demonstrates that patients in the HR-NBL1/
SIOPEN trial with stage 4 high-risk neuroblastoma who
had surgeon-assessed CME of the primary tumor had a
significantly higher survival. This improvement in 5-year
EFS and OS and lower local recurrence rate was evident in
the pre-immunotherapy and immunotherapy eras and was
achieved with a 9.7% severe operative complication rate
and 0.46% operative mortality. The association of CME with
improvement in EFS, OS, and CILP was further demon-
strated by multivariable analysis (Table 3).
The efficacy of induction therapy in reducing primary tumor
volume and vascularity, and thus allowing safer and ef-
fective excision, has been demonstrated in localized dis-
ease.34 Although chemotherapy may reduce IDRFs, they
are not usually eliminated.35,36 IDRFs were present in
77% of patients at surgery (Table 1) but were not considered
a contraindication to operation. IDRFs were identified by CT
scanning, as supported by studies that have demonstrated
that magnetic resonance imaging can underestimate
IDRFs after induction chemotherapy.37,38 We found no
relationship between IDRFs and survival; however, severe
complications were more common in the presence of
IDRFs (Data Supplement) and were less frequent with
CME, which may reflect a better response to chemother-
apy. The protocol advised against nephrectomy to preserve
renal function for HDT/SCT, as supported by a study that
found better survival in patients with bilateral renal pres-
ervation.39 Nephrectomy was only undertaken to facilitate
tumor excision, typically when the renal hilum was encased
by tumor. It was performed in 8.8% of patients (Table 1)
and was less frequent with CME compared with IME,
possibly because these tumors were easier to resect. There
was no difference in outcome (EFS, OS, and CILP) if excision
was postponed until after HDT. Operation is feasible at this
time but more challenging because the tumor is more
solid and calcified. It is an option if operation before HDT
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FIG 2. Outcome of the analysis population
with complete macroscopic excision
(CME) and incomplete macroscopic ex-
cision (IME). (A) Three- and 5-year event-
free survival (EFS), (B) overall survival
(OS), and (C) cumulative incidence of local
progression (CILP). Hazard ratios (HRs)
are adjusted for age, metastatic com-
partments, and end-of-induction meta-
static response (complete response, yes/
no; Table 3). pEFS, probability of event-
free survival; pOS, probability of overall
survival.
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complications or nephrectomy. Our recommendation is
that surgery be carried out as soon as technically feasible.
Excision during induction was not considered because
maintenance of the 10-day schedule of chemotherapy is
crucial to achieve dose intensity. In addition, the data
support operation at smaller centers by experienced sur-
geons, provided that they are SIOPEN-designated pediatric
oncology centers.
The percentage of patients in whom CME was achieved
(77%) is similar to that reported in a Children’s Oncology
Group study (70%).16 A higher frequency of CME with
MYCN-amplified tumors may have been due to their having
a greater mean reduction in primary tumor volume40 and
losing more IDRF35 compared with non–MYCN-amplified
tumors after induction therapy.
In this study, the protocol advised irradiation at a dose of
21 Gy to the preoperative volume of the primary tumor
and involved lymph nodes after HDT/SCR, irrespective of
the result of resection, although delivery of the full dose
was not always possible because of the tolerance of or-
gans at risk.41 Prophylactic radiotherapy was not given to
uninvolved lymph nodes, a practice that has been sup-
ported by a retrospective analysis.42 Radiotherapy was
withheld only if the radiotherapy coordinators considered
that the site and volume of the primary tumor made ra-
diotherapy a risk. This strategy differs from other studies14
where patients were irradiated, with a higher dose (40
Gy), if there was macroscopic postoperative residual
disease. The evidence for the value of radiotherapy in
high-risk neuroblastoma is limited,43 and a prospective
randomized trial is required to define precisely the
benefit. Defining the individual roles of the completeness
of surgical resection and radiotherapy in local control is
challenging because the effects of the two modalities are
intricately intermixed.
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FIG 3. Outcome of the analysis population comparing pre-immunotherapy (June 2002-June 2009) and immunotherapy (July 2009-December 2015)
periods. (A) Five-year event-free survival (EFS), (B) overall survival (OS), and (C) cumulative incidence of local progression (CILP). Hazard ratios (HRs) are
adjusted for age, metastatic compartments, and end-of-induction metastatic response (complete response, yes/no; Table 3). CME, complete mac-
roscopic excision; HR, hazard ratio; IME, incomplete macroscopic excision; pEFS, probability of event-free survival; pOS, probability of overall survival.
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TABLE 3. Multivariate Analysis of Risk Factors in Stage 4 High-Risk Neuroblastoma
EFS OS CILP
Model P HR (95% CI) P HR (95% CI) P Subdistribution HR (95% CI)
A. Total (n 5 1,297)
Age at diagnosis, years
# 1.5 1 1 1
. 1.5 .0370 1.3 (1 to 1.6) .1450 1.2 (0.9 to 1.5) .0800 1.4 (1 to 2.2)
MCs
1 1 1 1
. 1 , .0001 1.8 (1.4 to 2.2) , .0001 1.8 (1.4 to 2.3) .5920 0.9 (0.7 to 1.3)
Treatment period
$ July 2009 1 1 1
, June 2009 , .0001 1.5 (1.3 to 1.7) , .0001 1.6 (1.4 to 1.9) .0070 1.4 (1.1 to 1.8)
EOI metastatic response
CR 1 1 1
, CR .0430 1.2 (1 to 1.4) .2000 1.1 (0.9 to 1.3) .9340 1 (0.8 to 1.3)
Surgical result
CME 1 1
IME .0030 1.3 (1.1 to 1.5) .0050 1.3 (1.1 to 1.5) , .0001 2 (1.5 to 2.5)
B. 2002-June 2009 (n 5 656)
Age at diagnosis, years
# 1.5 1 1 1
. 1.5 .0260 1.4 (1 to 2) .0300 1.4 (1 to 2) .5500 1.2 (0.7 to 2)
MCs
1 1 1 1
. 1 , .0001 1.7 (1.3 to 2.3) , .0001 1.8 (1.3 to 2.4) .2510 0.8 (0.5 to 1.2)
EOI metastatic response
CR 1 1 1
, CR .0690 1.2 (1 to 1.5) .2580 1.1 (0.9 to 1.4) .6400 0.9 (0.7 to 1.3)
Surgical result
CME 1 1 1
IME .0300 1.3 (1 to 1.6) .0390 1.3 (1 to 1.6) , .0001 2.1 (1.5 to 2.9)
C. July 2009-2015 (n 5 641)
Age at diagnosis, years
# 1.5 1 1 1
. 1.5 .5010 1.1 (0.8 to 1.5) .8340 1 (0.7 to 1.3) .0770 1.8 (0.9 to 3.4)
MCs
1 1 1 1
. 1 .0080 1.9 (1.2 to 2.9) .0140 1.9 (1.1 to 3.1) .3600 1.4 (0.7 to 3.1)
EOI metastatic response
CR 1 1 1
, CR .3050 1.1 (0.9 to 1.4) .4750 1.1 (0.9 to 1.4) .4140 1.2 (0.8 to 1.8)
Surgical result
CME 1 1 1
IME .0380 1.3 (1 to 1.6) .0490 1.3 (1 to 1.7) .0020 1.8 (1.2 to 2.7)
NOTE. Risk factors that were not significant (at the 5 level) for EFS in the univariable analysis (Table 2;MYCN amplification, primary tumor site,
presence of IDRFs, time point of operation, surgical complications, nephrectomy, center size) were not included in the multivariable analysis.
Abbreviations: CILP, cumulative incidence of local progression; CME, completemacroscopic excision; CR, complete response; EFS, event-free
survival; EOI, end of induction; HR, hazard ratio; IDRF, image-defined risk factor; IME, incomplete macroscopic excision; MC, metastatic
compartment; OS, overall survival.
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The added benefit of surgical excision to survival in high-
risk neuroblastoma is difficult to delineate, and there are
conflicting reports.9-19 Consistent with a systematic review19
and many reports,9-12,15,16 we were able to demonstrate
a significantly lower incidence of local disease progression
(CILP) after CME compared with IME (Fig 2). In contrast to
this analysis, a report from the German Society for Pediatric
Oncology and Hematology (GPOH)14 in which only 28
(10%) of 278 patients received radiotherapy demonstrated
that 54.7% of patients had complete excision after in-
duction chemotherapy but showed no relationship between
the extent of surgical excision and survival. Our results are
corroborated by the previous findings of the COG A3973
trial16 and are complementary, rather than contradictory, to
the results of the GPOH NB97 study, which suggests that
the combination of surgery with radiotherapy is required to
achieve local control in high-risk neuroblastoma.16,44,45
Supportive data for an improved local control rate after
radiotherapy were also demonstrated in the CCG-3891
trial.16 This might argue for a higher dose of radiotherapy in
patients with macroscopic residual disease and will be
a randomized question in the next SIOPEN high-risk
neuroblastoma trial.
It is possible that CME is associated with favorable tumor
biologic features and that tumor biology is driving both the
ease of achieving a CME and better survival. However, this
cannot be assessed in the current analysis, and to date,
these favorable tumor biologic features and relationship
with age have not been identified.
Assessment of CME and IME was based on surgeon as-
sessment at the conclusion of operation, and the volume of
the residue was not quantified. When designing the trial,
the trial radiology committee did not consider that con-
temporary imaging would discriminate between residual
disease and the tissue effects of operation. This is sup-
ported by studies (including a contemporary European
study; S. Irtan, personal communication, April 2020) where
discordance was found in 33%, 37%, and 42% of patients
when the degree of resection was determined by post-
operative imaging and surgical assessment.16,46 The dis-
cordancemay be due to variation in the time of imaging and
different imaging techniques, and that any imaging tech-
nique, except positive tumor avidity on MIBG single-photon
emission CT may not be sufficiently accurate to discrimi-
nate tumor from the effects of operation. In the next
SIOPEN high-risk study, HR-NBL2, postoperative cross-
sectional imaging at a specified time is planned to compare
surgically assessed resection with that determined by im-
aging. Histopathologic examination of the resected speci-
men cannot confirm the completeness of excision because
tumors are usually not removed en bloc, and the clear
margins used to define complete excision in other tumor
types cannot be applied to neuroblastoma, where the tumor
margin is often the wall of a major blood vessel. The pro-
posed consensus on surgical terminology will facilitate
comparisons between reports of investigations by inter-
national trial cooperative groups.47
To our knowledge, this study of 1,531 patients is the largest
analysis of the influence of surgical excision on the survival
of patients with stage 4 high-risk neuroblastoma in a single
trial to date. An improvement in survival and a reduction in
local progression were associated with CME and radiotherapy
to the preoperative volume of the primary tumor and involved
regional lymph nodes. Furthermore, the association of CME
with a superior outcome persisted with immunotherapy using
dinutuximab beta. In conclusion, the low severe operative
complication and mortality rates justify determined attempts
at CME of the primary tumor after appropriate chemotherapy.
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